Short Dual Antithrombotic Therapy After PCI In Patients With Atrial Fibrillation: The OPTIMA-AF Trial
The OPTIMA-AF trial demonstrated that among patients with atrial fibrillation undergoing PCI, one month of dual antithrombotic therapy was noninferior to 12 months of dual therapy for the 12-month composite of death or thromboembolic events, and was associated with significantly lower rates of major bleeding or clinically relevant nonmajor bleeding, according to a study presented by Dr. Yohei Sotomi,The University of Osaka, Japan, in the Late-Breaking Science session at the AHA Scientific Sessions 2025.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
